Journal
FRONTIERS IN IMMUNOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2020.00580
Keywords
CD8 T cell; YAP; tumor; immunesuppression; hippo
Categories
Funding
- Bloomberg-Kimmel Institute (Immunometabolism Program & Immune Modulation Program)
- Melanoma Research Alliance
- National Institutes of Health [RO1AI099300, RO1AI089830, R01AI137646, R01CA218270]
- Department of Defense [PC130767]
Ask authors/readers for more resources
YAP is a transcriptional coactivator of the Hippo signaling pathway that has largely been studied for its role in the regulation of organ size during development. Several studies have shown that YAP is upregulated in cancer cells, and more recently in the T regulatory (Treg) subset of CD4+ cells. These observations suggest that the transcriptional co-activator may promote tumor persistence and progression. Here, we report that YAP also plays an immunoinhibitory role in CD8 T cells, especially in activated cytotoxic cells usually found in the tumor microenvironment. Our findings add further rationale for the development and use of pharmacologic inhibitors of YAP to treat cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available